NOTCH3 mutation	Non Small Cell Lung Cancer	NOTCH3 mutation	Non Small Cell Lung Cancer	tislelizumab-jsgr Sensitive: B - Late Trials tislelizumab-jsgr Sensitive : B	tislelizumab-jsgr Sensitive: B - Late Trials tislelizumab-jsgr Sensitive : B
NOTCH3 overexpression	Pancreatic Cancer	NOTCH3 overexpression	Pancreatic Cancer	OMP-59R5 Sensitive: C2 – Inclusion Criteria OMP-59R5 Sensitive : C2	OMP-59R5 Sensitive: C2 – Inclusion Criteria OMP-59R5 Sensitive : C2
NOTCH3 mutation	Non Small Cell Lung Cancer	NOTCH3 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
NOTCH3 mutation	Colorectal Cancer	NOTCH3 mutation	Colorectal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
NOTCH3 mutation	Solid Tumor	NOTCH3 mutation	Solid Tumor	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
NOTCH3 underexpression	Urothelial Cancer	NOTCH3 underexpression	Urothelial Cancer	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3
NOTCH3 expression	Estrogen Receptor Positive Breast Cancer	NOTCH3 expression	Estrogen Receptor Positive Breast Cancer	PF-06650808 Sensitive: C3 – Early Trials PF-06650808 Sensitive : C3	PF-06650808 Sensitive: C3 – Early Trials PF-06650808 Sensitive : C3
NOTCH3 expression + ER positive + PGR positive	HER2 Negative Breast Cancer	NOTCH3 expression + ER positive + PGR positive	HER2 Negative Breast Cancer	PF-06650808 Sensitive: C3 – Early Trials PF-06650808 Sensitive : C3	PF-06650808 Sensitive: C3 – Early Trials PF-06650808 Sensitive : C3

NOTCH3 (Notch Receptor 3)

Associations(8)

Associations
(8)